Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations [Phase 3]
A Phase 3 trial compares almonertinib to placebo as adjuvant therapy after surgical resection in stage II-IIIB non-small cell lung cancer wi…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI [Phase 2]
A Phase 2 trial assessing rechallenge with immune checkpoint inhibitors in advanced Non-small cell lung cancer patients who previously had a…
-
EMA withdrawal · 2024-11-06EMA Withdrawn: Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) — Sandoz GmbH
The European Medicines Agency has withdrawn Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) from the European market. It was indica…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination [Phase 1]
Pfizer's Phase 1 study of PF-07329640, given alone or in combination, in advanced/metastatic solid tumors including non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment [Phase 1]
A Phase 1 trial evaluating safety of immunotherapy induction with tremelimumab and durvalumab before chemoradiotherapy and/or resection in S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients [Phase 2]
A Phase 2 trial in ALK-positive non-small cell lung cancer evaluates the activity of lorlatinib in relation to ALK resistance mutations dete…
-
CLINICAL_TRIALS research · 2024-11-05Clinical Trial Update: Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations [Phase 3]
Phase 3 trial evaluating furmonertinib 160 mg as first-line therapy for locally advanced or metastatic non-small cell lung cancer with EGFR …
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: Functional Lung Imaging With DECT and 4DCT
A completed clinical trial evaluated functional lung imaging using dual-energy CT (DECT) and 4DCT in patients with Non-Small Cell Lung Cance…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours [Phase 1]
This clinical trial update reports the completion of a first-in-human Phase 1 study evaluating AZD8701 with or without durvalumab in adults …
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit [NA]
The document provides an update on a completed clinical performance study protocol for the Therascreen KRAS RGQ PCR Kit in non-small cell lu…
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 [Phase 1]
Phase 1 study of MT-6402 in PD-L1-expressing advanced solid tumors, including non-small cell lung cancer and squamous cell carcinoma of the …
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR Kit [NA]
A completed clinical study evaluating DNA extracted from tumor tissue biopsies using the Therascreen KRAS RGQ PCR Kit in non-small cell lung…
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit
Completed clinical trial evaluating the Therascreen KRAS RGQ PCR Kit for analyzing DNA from tumor tissue biopsies in non-small cell lung can…
-
CLINICAL_TRIALS research · 2024-11-04Clinical Trial Update: Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of the investigational drug HS-10375 for advanced or metastatic non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients [Phase 3]
Phase 3 trial comparing SAR408701 to docetaxel in CEACAM5-positive metastatic non-squamous non-small cell lung cancer has posted results and…
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types [Phase 1]
A Phase 1 study evaluating MT-8421 as monotherapy and in combination with nivolumab in selected advanced solid tumors has been terminated. T…
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer [Phase 3]
Phase 3 study comparing Ociperlimab plus Tislelizumab vs Durvalumab after concurrent chemoradiotherapy in stage III unresectable non-small c…
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer [NA]
A completed study evaluating a cognitive-behavioral model to reduce dyspnea in patients with lung cancer has been reported.
-
CLINICAL_TRIALS research · 2024-10-31Clinical Trial Update: Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC [Phase 2]
A Phase 2 study is evaluating osimertinib plus stereotactic radiosurgery (SRS) versus osimertinib alone in patients with EGFR-positive non-s…
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy [Phase 2]
This Phase 2 clinical trial evaluates the efficacy of low-dose nivolumab added to chemotherapy as neoadjuvant treatment for non-small cell l…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy [Phase 2]
Phase 2 trial evaluating tislelizumab for stage III non-small cell lung cancer after neoadjuvant therapy, with optional bevacizumab and defi…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 2]
A Phase 2 study evaluating the combination of vinorelbine and bevacizumab in older adults with stage III or stage IV non-small cell lung can…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers [Phase 1]
This document reports a Phase 1 clinical trial of NI-1801 for mesothelin-expressing solid cancers, with recruiting status and multiple indic…
-
CLINICAL_TRIALS research · 2024-10-28Clinical Trial Update: Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer [NA]
The trial evaluating stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer is currently active but not recruitin…
-
CLINICAL_TRIALS research · 2024-10-28Clinical Trial Update: A Study of XZB-0004 in Patients With Solid Tumors [Phase 1]
Phase 1 study of XZB-0004 in patients with solid tumors, including non-small cell lung cancer, is currently recruiting.